OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

What happened: OpenAI acquired Orchestra Bio, a four-year-old AI biotech software startup, and is adding its team and technology to work on Rosalind, its AI model for life sciences research, and the Rosalind Workbench tool. Key numbers: Deal terms were not disclosed. Why it matters: OpenAI says Rosalind already counts Moderna and Novo Nordisk as customers. The deal reflects big AI labs building more software for major industries like pharma, and startups' fear that labs will launch competing features. Coverage: 4 outlets in 24h

OpenAI acquired Orchestra Bio, a four-year-old AI biotech software startup, and is adding its team and technology to work on Rosalind, its AI model for life sciences research, and the Rosalind Workbench tool.

OpenAI says Rosalind already counts Moderna and Novo Nordisk as customers. The deal reflects big AI labs building more software for major industries like pharma, and startups' fear that labs will launch competing features.